Gri Bio Etf Price To Earnings To Growth
| GRI Etf | USD 0.76 0.03 4.11% |
GRI Bio fundamentals help investors to digest information that contributes to GRI Bio's financial success or failures. It also enables traders to predict the movement of GRI Etf. The fundamental analysis module provides a way to measure GRI Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to GRI Bio etf.
GRI |
GRI Bio ETF Price To Earnings To Growth Analysis
GRI Bio's PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Based on the latest financial disclosure, GRI Bio has a Price To Earnings To Growth of 0.0 times. This indicator is about the same for the Biotechnology average (which is currently at 0.0) family and about the same as Health Care (which currently averages 0.0) category. This indicator is about the same for all United States etfs average (which is currently at 0.0).
GRI Price To Earnings To Growth Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses GRI Bio's direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the etfs which would be a good addition to a portfolio. Peer analysis of GRI Bio could also be used in its relative valuation, which is a method of valuing GRI Bio by comparing valuation metrics of similar companies.GRI Bio is currently under evaluation in price to earnings to growth as compared to similar ETFs.
Fund Asset Allocation for GRI Bio
The fund invests 99.63% of asset under management in tradable equity instruments, with the rest of investments concentrated in various types of exotic instruments.Asset allocation divides GRI Bio's investment portfolio among different asset categories to balance risk and reward by investing in a diversified mix of instruments that align with the investor's goals, risk tolerance, and time horizon. Mutual funds, which pool money from multiple investors to buy a diversified portfolio of securities, use asset allocation strategies to manage the risk and return of their portfolios.
Mutual funds allocate their assets by investing in a diversified portfolio of securities, such as stocks, bonds, cryptocurrencies and cash. The specific mix of these securities is determined by the fund's investment objective and strategy. For example, a stock mutual fund may invest primarily in equities, while a bond mutual fund may invest mainly in fixed-income securities. The fund's manager, responsible for making investment decisions, will buy and sell securities in the fund's portfolio as market conditions and the fund's objectives change.
GRI Fundamentals
| Return On Equity | -1.89 | ||||
| Return On Asset | -0.83 | ||||
| Current Valuation | 2.17 M | ||||
| Shares Outstanding | 8.93 M | ||||
| Shares Owned By Insiders | 0.35 % | ||||
| Shares Owned By Institutions | 4.70 % | ||||
| Number Of Shares Shorted | 205.97 K | ||||
| Price To Earning | 23.35 X | ||||
| Price To Book | 1.85 X | ||||
| Revenue | 21.77 M | ||||
| EBITDA | (10.9 M) | ||||
| Net Income | (13.04 M) | ||||
| Cash And Equivalents | 183.82 M | ||||
| Cash Per Share | 0.30 X | ||||
| Total Debt | 14 K | ||||
| Debt To Equity | 1.23 % | ||||
| Current Ratio | 5.23 X | ||||
| Book Value Per Share | 5.21 X | ||||
| Cash Flow From Operations | (9.14 M) | ||||
| Short Ratio | 0.10 X | ||||
| Earnings Per Share | 77.53 X | ||||
| Target Price | 12.0 | ||||
| Market Capitalization | 6.79 M | ||||
| Total Asset | 2.96 M | ||||
| Retained Earnings | (31.53 M) | ||||
| Working Capital | 237 K | ||||
| Current Asset | 1.22 B | ||||
| Current Liabilities | 243.82 M | ||||
| One Year Return | 12.82 % | ||||
| Three Year Return | 8.99 % | ||||
| Five Year Return | 5.20 % | ||||
| Ten Year Return | 8.79 % | ||||
| Net Asset | 2.96 M | ||||
| Last Dividend Paid | 0.51 | ||||
| Equity Positions Weight | 99.63 % |
About GRI Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze GRI Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GRI Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GRI Bio based on its fundamental data. In general, a quantitative approach, as applied to this etf, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in GRI Etf
GRI Bio financial ratios help investors to determine whether GRI Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in GRI with respect to the benefits of owning GRI Bio security.